DTNA encodes dystrobrevin alpha (743 aa). May be involved in the formation and stability of synapses as well as being involved in the clustering of nicotinic acetylcholine receptors Highest expression in Brain Spinal cord cervical c-1 (84.4 TPM) and Brain Hypothalamus (62.3 TPM).

Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2 is associated with mutations in the DTNA gene on chromosome 18.

The DTNA protein participates in Recruitment of dystrophin, dystrobrevin and syntrophin proteins to the DGC pathway.

DTNA is classified as a druggable target with score 1.6.

Genetic testing for DTNA is available. Testing is considered confirmatory for diagnosis.

Biomarker and diagnostic research for myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2 has been reported in the published literature.

No clinical trials have been registered for myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2.

46 publications have been identified in PubMed for myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2. Research spans Case Report / Case Series (42%), Review / Meta-Analysis (21%), and Epidemiology / Natural History (14%).